Literature DB >> 35525874

Pericardial effusion in giant cell arteritis is associated with increased inflammatory markers: a retrospective cohort study.

Quentin Gomes de Pinho1, Aurélie Daumas2, Audrey Benyamine3, Julien Bertolino3, Pascal Rossi3, Nicolas Schleinitz4, Jean-Robert Harlé4, Pierre André Jarrot5, Gilles Kaplanski5, Julie Berbis6, Brigitte Granel3.   

Abstract

OBJECTIVE: Giant cell arteritis (GCA) is the most frequent vasculitis affecting adults aged > 50 years. Cardiac involvement in GCA is considered rare, and only a few cases of pericarditis have been reported. The aim of this study was to determine the characteristics and prognosis of GCA patients suffering from pericardial involvement at diagnosis.
METHODS: We conducted a single-centre, retrospective chart review of patients with GCA in internal medicine departments (from 2000 to 2020). Patients were identified through a centralized hospital database. We retrospectively collected demographic, clinicobiological, histological, imaging, treatment and outcome data. Patients with pericardial effusion, defined as an effusion visible on the CT-scan performed at GCA diagnosis were compared to those without pericardial involvement.
RESULTS: Among the 250 patients with GCA, 23 patients (9.2%) had pericardial effusion on CT-scan. The comparison between the groups revealed similar distribution of age, gender, cranial symptoms and ocular ischaemic complications. Patients with pericardial effusion had a higher frequency of weight loss. They also had lower haemoglobin levels and higher platelet levels (p = 0.006 and p = 0.002, respectively), and they more frequently had positive temporal artery biopsy. There were no differences concerning the treatment, relapses, follow-up duration or deaths.
CONCLUSIONS: This case series sheds light on GCA as a cause of unexplained pericardial effusion or symptomatic pericarditis among adults aged > 50 years and elevated inflammatory biological markers. Fortunately, pericardial involvement is a benign GCA manifestation. In that context, the search for constitutional symptoms, cranial symptoms and associated signs of polymyalgia rheumatica is crucial for rapidly guiding GCA diagnosis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Giant cell arteritis; Horton’s disease; Pericardial effusion; Pericarditis

Mesh:

Substances:

Year:  2022        PMID: 35525874     DOI: 10.1007/s00296-022-05137-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  24 in total

1.  Myopericarditis revealing giant cell arteritis in the elderly.

Authors:  Aurélie Daumas; Pascal Rossi; Alexis Jacquier; Brigitte Granel
Journal:  J Rheumatol       Date:  2012-03       Impact factor: 4.666

2.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

3.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  Carlo Salvarani; Luca Cimino; Pierluigi Macchioni; Dario Consonni; Fabrizio Cantini; Gianluigi Bajocchi; Nicolò Pipitone; Maria Grazia Catanoso; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-04-15

4.  Giant cell arteritis associated with pericarditis and large vessel disease.

Authors:  D Stanley; D Henderson; S Harris
Journal:  Aust N Z J Med       Date:  1991-06

5.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Authors:  Bernhard Hellmich; Ana Agueda; Sara Monti; Frank Buttgereit; Hubert de Boysson; Elisabeth Brouwer; Rebecca Cassie; Maria C Cid; Bhaskar Dasgupta; Christian Dejaco; Gulen Hatemi; Nicole Hollinger; Alfred Mahr; Susan P Mollan; Chetan Mukhtyar; Cristina Ponte; Carlo Salvarani; Rajappa Sivakumar; Xinping Tian; Gunnar Tomasson; Carl Turesson; Wolfgang Schmidt; Peter M Villiger; Richard Watts; Chris Young; Raashid Ahmed Luqmani
Journal:  Ann Rheum Dis       Date:  2019-07-03       Impact factor: 19.103

Review 6.  Giant Cell Arteritis (GCA): Pathogenesis, Clinical Aspects and Treatment Approaches.

Authors:  Andrea Ciofalo; Giampiero Gulotta; Giannicola Iannella; Benedetta Pasquariello; Alessandra Manno; Diletta Angeletti; Annalisa Pace; Antonio Greco; Giancarlo Altissimi; Marco de Vincentiis; Giuseppe Magliulo
Journal:  Curr Rheumatol Rev       Date:  2019

7.  Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.

Authors:  Hubert de Boysson; Eric Liozon; Olivier Espitia; Aurélie Daumas; Mathieu Vautier; Marc Lambert; Jean-Jacques Parienti; Brigitte Granel; Anael Dumont; Audrey Sultan; Alain Manrique; David Saadoun; Kim Heang Ly; Christian Agard; Achille Aouba
Journal:  J Autoimmun       Date:  2019-05-24       Impact factor: 7.094

Review 8.  Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients.

Authors:  Hubert de Boysson; Aurélie Daumas; Mathieu Vautier; Jean-Jacques Parienti; Eric Liozon; Marc Lambert; Maxime Samson; Mikael Ebbo; Anael Dumont; Audrey Sultan; Bernard Bonnotte; Alain Manrique; Boris Bienvenu; David Saadoun; Achille Aouba
Journal:  Autoimmun Rev       Date:  2018-02-07       Impact factor: 9.754

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

10.  A meta-analysis of the epidemiology of giant cell arteritis across time and space.

Authors:  Katherine J Li; Daniel Semenov; Matthew Turk; Janet Pope
Journal:  Arthritis Res Ther       Date:  2021-03-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.